Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Iron Dosing for Childhood RLS/PLMD
NCT04610827Phase 4Terminated
- Sponsor
- Mayo Clinic
- Start
- Nov 2020
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ferrous sulfate in restless legs syndrome (RLS) and periodic limb movement disorder (PLMD) (3 arms), sponsored by Mayo Clinic. Primary endpoints: Ferritin Level at 2 months and Side Effects at 2 months. Started Nov 2020; status: terminated.
02
Drugs
ferrous sulfate
03
Conditions
restless legs syndrome (RLS)periodic limb movement disorder (PLMD)
Beyond the preview
Go deeper on NCT04610827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04610827.